ABL1 E255K

CI-VAR-00000703Explore in graph →NP_005148.2:p.Glu255LysNM_005157.5:c.763G>AClinVar 376090 CIViC 3 rs121913448

Curated evidence

Evidence by cancer (26 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–26 of 26 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Acute Lymphoblastic Leukemia1
BCR::ABL1 Fusion AND ABL1 E255K	Dasatinib	Predictive	C	Supports Resistance	3	accepted	EID4718 Prior to dasatinib treatment, one imatinib-resistant patient with acute lymphoblastic leukemia had the BCR-ABL1 fusion with the E255K secondary variant in 3/12 bacterial clones generated using periphe… (full text at CIViC) PMID 16775234 · Talpaz et al., 2006 · Open in CIViC	civic
Chronic Myeloid Leukemia, BCR-ABL1 Positive25
ABL1 E255K	Dasatinib	Predictive	D	Supports Resistance	2	rejected	EID6283 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.